Comparative Pharmacology
Head-to-head clinical analysis: NEO FRADIN versus UCEPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO FRADIN versus UCEPHAN.
NEO-FRADIN vs UCEPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
UCEPHAN (eculizumab) is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing the formation of the membrane attack complex (MAC) and terminal complement-mediated cell lysis.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
500 mg orally every 12 hours or 250 mg orally every 8 hours.
None Documented
None Documented
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Terminal elimination half-life is 2.1 ± 0.5 hours in adults with normal renal function; prolonged to 20–50 hours in severe renal impairment (CrCl <10 mL/min).
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Approximately 70–80% of an administered dose is eliminated unchanged in urine via glomerular filtration and tubular secretion; the remainder (20–30%) is eliminated via biliary/fecal routes, with <5% as metabolites.
Category C
Category C
Antibiotic
Antibiotic, Cephalosporin